February 10-11
April 7-8
June 9-10
August 11-12
October 13-14
December 8-9
One of our representatives will happily contact you. Please call us at 773-440-4241
Welcome to the RUSH Hemophilia & Thrombophilia Center Provider Shadow Program (PSP) website. The PSP is an experience to enhance the care provided to people with bleeding disorders. Thank you for viewing this site and considering participating in the educational opportunities available through the PSP.
The mission of the Rush HTC is to provide: State-of-the-art medical management to patients with bleeding and clotting disorders to limit complications and promote good health. Expert physical therapy and orthopedic intervention to prevent chronic joint problems and promote physical well being.
February 10-11
April 7-8
June 9-10
August 11-12
October 13-14
December 8-9
A Hemophilia Treatment Center (HTC) is a functional unit organized for and capable of providing coordinated, multi-disciplinary comprehensive care for persons with hemophilia and related bleeding disorders. Its purpose is to provide the comprehensive health care services necessary for the accurate diagnosis and continuing expert evaluation and management of inherited bleeding disorders and their complications.
Hemophilia Treatment Center
MASAC is the abbreviation for the Medical and Scientific Advisory Council. This special council was established by the National Hemophilia Foundation in 1954 to further clinical care and to support research related to bleeding disorders. This council helps institute medical care guidelines for the treatment of bleeding disorders
MASAC
UDC is the abbreviation for Universal Data Collection. The UDC is a special clinical research project of the Centers for Disease Control and Prevention (CDC) aimed at monitoring blood safety and preventing complications for persons with bleeding disorders. Data collected from participating patients (after providing written informed consent) helps the CDC to establish a uniform set of clinical outcomes that are used to monitor occurrence of possible risk factors for infectious disease and joint complications. This data is collected during the comprehensive hemophilia evaluation.
UDC